Literature DB >> 9170361

The cerebral palsied hip.

B E Black1, P P Griffin.   

Abstract

Controversy exists regarding the role of pelvic obliquity in hip dysplasia and cerebral palsy. Earlier authors noted such a relationship but did not confirm its existence by scientific study. The current study confirms the association of pelvic obliquity to hip dysplasia in spastic cerebral palsy. At presentation of subluxation or dislocation before surgery, 80 patients were indexed into 5 body alignment types. Reclassifications were performed with passage of time to study the natural history and effects of surgery. Hip dysplasia was found in all cases to be consistent with the forces related to pelvic obliquity.

Entities:  

Mesh:

Year:  1997        PMID: 9170361     DOI: 10.1097/00003086-199705000-00007

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  4 in total

1.  [Total hip arthroplasty in cerebral palsy].

Authors:  C M Schörle; G Fuchs; G Manolikakis
Journal:  Orthopade       Date:  2006-08       Impact factor: 1.087

2.  [Surgical treatment of secondary hip dislocation in cerebral palsy].

Authors:  C M Schörle; G Manolikakis
Journal:  Orthopade       Date:  2004-10       Impact factor: 1.087

3.  Long-term results of hip arthroplasty in ambulatory patients with cerebral palsy.

Authors:  Kerstin Schroeder; Christian Hauck; Bernd Wiedenhöfer; Frank Braatz; Peter R Aldinger
Journal:  Int Orthop       Date:  2009-04-22       Impact factor: 3.075

4.  Australian Cerebral Palsy Child Study: protocol of a prospective population based study of motor and brain development of preschool aged children with cerebral palsy.

Authors:  Roslyn N Boyd; Rachel Jordan; Laura Pareezer; Anne Moodie; Christine Finn; Belinda Luther; Evyn Arnfield; Aaron Pym; Alex Craven; Paula Beall; Kelly Weir; Megan Kentish; Meredith Wynter; Robert Ware; Michael Fahey; Barry Rawicki; Lynne McKinlay; Andrea Guzzetta
Journal:  BMC Neurol       Date:  2013-06-11       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.